Of clinical relevance, in HG-SOC patients, which accounts for 70–80% of ovarian cancer deaths, an ETAR/ZEB1 signature is associated with poor prognosis, highlighting the worse outcomes generated by the integration between ETAR and ZEB1 transcriptional machinery for these patients still suffering from limited treatment option. This evidence concerns the gene ZEB1 and ovarian carcinoma.